2seventy bio, Inc.: 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from